These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25525034)

  • 1. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.
    Lathrop MJ; Sage EK; Macura SL; Brooks EM; Cruz F; Bonenfant NR; Sokocevic D; MacPherson MB; Beuschel SL; Dunaway CW; Shukla A; Janes SM; Steele C; Mossman BT; Weiss DJ
    Cancer Gene Ther; 2015 Jan; 22(1):44-54. PubMed ID: 25525034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.
    Sage EK; Kolluri KK; McNulty K; Lourenco Sda S; Kalber TL; Ordidge KL; Davies D; Gary Lee YC; Giangreco A; Janes SM
    Thorax; 2014 Jul; 69(7):638-47. PubMed ID: 24567297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
    Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
    Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway.
    Yang X; Du J; Xu X; Xu C; Song W
    J Immunol Res; 2014; 2014():318098. PubMed ID: 24971369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
    Luetzkendorf J; Mueller LP; Mueller T; Caysa H; Nerger K; Schmoll HJ
    J Cell Mol Med; 2010 Sep; 14(9):2292-304. PubMed ID: 19508388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.
    Cafforio P; Viggiano L; Mannavola F; Pellè E; Caporusso C; Maiorano E; Felici C; Silvestris F
    Stem Cell Res Ther; 2017 Sep; 8(1):206. PubMed ID: 28962646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
    Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
    Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells.
    Xia P; Wang W; Bai Y
    Apoptosis; 2014 Mar; 19(3):491-505. PubMed ID: 24242915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRAIL-overexpressing Adipose Tissue-derived Mesenchymal Stem Cells Efficiently Inhibit Tumor Growth in an H460 Xenograft Model.
    Un Choi Y; Yoon Y; Jung PY; Hwang S; Hong JE; Kim WS; Sohn JH; Rhee KJ; Bae KS; Eom YW
    Cancer Genomics Proteomics; 2021; 18(4):569-578. PubMed ID: 34183389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.
    Mohr A; Lyons M; Deedigan L; Harte T; Shaw G; Howard L; Barry F; O'Brien T; Zwacka R
    J Cell Mol Med; 2008 Dec; 12(6B):2628-43. PubMed ID: 18373740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
    Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice.
    Yoon N; Park MS; Peltier GC; Lee RH
    Cytotherapy; 2015 Oct; 17(10):1332-41. PubMed ID: 26227206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo.
    Salmasi Z; Hashemi M; Mahdipour E; Nourani H; Abnous K; Ramezani M
    Biotechnol Prog; 2020 Nov; 36(6):e3025. PubMed ID: 32410328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
    Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
    Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.
    Xia L; Peng R; Leng W; Jia R; Zeng X; Yang X; Fan M
    J Dent Res; 2015 Jan; 94(1):219-28. PubMed ID: 25391621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models.
    Guiho R; Biteau K; Grisendi G; Chatelais M; Brion R; Taurelle J; Renault S; Heymann D; Dominici M; Redini F
    Cytotherapy; 2018 Aug; 20(8):1037-1045. PubMed ID: 30093324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.
    Yoon N; Park MS; Shigemoto T; Peltier G; Lee RH
    Cell Death Dis; 2016 Apr; 7(4):e2191. PubMed ID: 27077807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
    Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
    Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.